Glepaglutide (5mg)
Long-Acting GLP-2 Analog for Intestinal Adaptation Research
Glepaglutide is listed for GLP-2 pathway research. Catalog vial contents are 5mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Long-acting GLP-2 receptor agonism
- Intestinal mucosal-adaptation research tool
- Twice-weekly subcutaneous dosing in research models
- Mechanism distinct from GLP-1 incretin class
What is Glepaglutide?
Zealand Pharma's long-acting GLP-2 receptor agonist developed for short-bowel-syndrome research — distinct from the GLP-1 class, with a focus on intestinal mucosal growth and absorption.
Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Glepaglutide (ZP1848) is a synthetic, long-acting analog of glucagon-like peptide-2 (GLP-2), a 33-amino-acid intestinotrophic hormone released from intestinal L-cells. Mechanistically distinct from GLP-1 / GIP, glepaglutide drives crypt-cell proliferation, villus elongation, increased intestinal blood flow, and enhanced nutrient and fluid absorption through GLP-2R on enteroendocrine and subepithelial myofibroblast cells.
What are the research questions?
- Short bowel syndrome research: EASE-1 Phase 3 evaluated glepaglutide for reduction of parenteral support volume in adults with SBS and intestinal failure.
- Intestinal-adaptation research: Used in models studying GLP-2-driven mucosal growth, crypt-villus axis remodeling, and barrier-function recovery.
- GI surgical recovery research: Investigated for post-resection adaptation in preclinical models.
- GLP-2-pathway pharmacology: Provides a long-acting comparator to teduglutide in receptor-occupancy and downstream signaling studies.
What does the published work describe?
Naimi RM et al. (Lancet Gastroenterol Hepatol 2019) — Phase 2 demonstrated significant absorption improvements in SBS patients. Zealand Pharma EASE-1 Phase 3 (2023) reported reductions in parenteral support volume vs placebo in adults with SBS-IF.
What are the limits of this evidence?
The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.
Study references
- Naimi RM et al. Lancet Gastroenterol Hepatol 2019 — glepaglutide Phase 2
- Zealand Pharma EASE-1 Phase 3 disclosure, 2023
- Drucker DJ, Yusta B. Annu Rev Physiol 2014 — GLP-2 pharmacology
These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Glepaglutide handled in the lab?
For Glepaglutide, record the product code GLEP-5, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for Glepaglutide from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
For Glepaglutide, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4400 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Glepaglutide form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Glepaglutide laboratory protocol should record identity, product code GLEP-5, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Glepaglutide
- CAS Number
- 1825266-87-4
- Molecular Weight
- ~4400 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- GLP-1 & Metabolic
- Starting Price
- $169.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Glepaglutide has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Glepaglutide?
Glepaglutide is listed for GLP-2 pathway research. Catalog vial contents are 5mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Glepaglutide are available?
The catalog lists 5mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Glepaglutide purity results?
Glepaglutide has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Glepaglutide be handled in the laboratory?
For Glepaglutide, record the product code GLEP-5, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Glepaglutide?
Choose a solvent for Glepaglutide from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
How do I calculate a Glepaglutide stock concentration?
For Glepaglutide, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4400 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Glepaglutide be stored after preparation?
Use the documented storage conditions for the supplied Glepaglutide form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Glepaglutide lab protocol document?
A Glepaglutide laboratory protocol should record identity, product code GLEP-5, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Glepaglutide product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this Glepaglutide lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is Glepaglutide for human use?
No. Glepaglutide is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
